Unfractionated heparin therapy in infants and children

Pediatrics

Volumn 123, Issue 3, 2009, Pages

  Newall, Fiona ^a,b   Johnston, Linda ^a,b   Ignjatovic, Vera ^a,b   Monagle, Paul ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Anticoagulation; Drug safety; Hematology; Laboratory medicine; Unfractionated heparin

Indexed keywords

ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; ANTICOAGULANT AGENT;

BLEEDING; CLINICAL TRIAL; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; ADOLESCENT; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; DOSE RESPONSE; DRUG TOXICITY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME;

ADOLESCENT; AGE FACTORS; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HEMORRHAGE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; LONG-TERM CARE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 63149124872     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-2052     Document Type: Review

References (70)

1. Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopaenia in children. J Paediatr Child Health. 2003; 39(4):289-292
2. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analysis of the Canadian registry of VTE. Blood. 1994;83(5):1251-1257
3. Andrew M, David M, de Veber G, Brooker L. Arterial thrombembolic complications in paediatric patients. Thromb Haemost. 1997;78(1):715-725
4. Andrew M, Monagle P, Brooker L. Thromboembolic Complications During Infancy and Childhood. Hamilton, Ontario, Canada: BC Decker; 2000
5. Clark D. Venous thromboembolism in paediatric practice. Pae-diatr Anaesth. 1999;9(6):475-484
6. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 1995; 96(5 pt 1):939-943
7. Newall F, SavoiaH, CampbellJ, et al. Venous thromboembolic disease: a single-centre case series study. JPaediatr Child Health. 2006;42(12):803-807
8. Newall F, Savoia H, Campbell J, et al. Arterial thromboembolic disease: a single-centre case series study. J Paediatr Child Health. 2008;44(1-2):28-32
9. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):887S-968S
10. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A. Antithrombotic therapy in children. Chest. 2004;126(3 suppl): 645S-687S
11. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35(1):78-83
12. deVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol. 1998;55(12):1533-1537
13. David M, Andrew M. Venous thromboembolic complications in children. J Pediatr. 1993;123(5 pt 1):337-346
14. Massicotte P, Julian J, Gent M, et al. An open-labelrandomized controlled trial of low molecular weight heparin compared to heparin and Coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res. 2003; 109(2-3):85-92
15. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res. 2000;47(6):763-766
16. Ino T, Benson L, Freedom R, et al. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J. 1988;115(3):633-639
17. Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation. 1974;50(3):565-569
18. Kuhle S, Eulmesekian P, Kavanagh B, et al. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica. 2007;92(2):244-247
19. McDonald M, Hathaway W. Anticoagulation therapy by continuous heparinization in newborn and older infants. J Pediatr. 1982;101(3):451-457
20. Schmidt B, Andrew M. Report of Scientific and Standardization Subcommittee on Neonatal Hemostasis Diagnosis and Treatment of Neonatal Thrombosis. Thromb Haemost. 1992; 67(3):381-382
21. Sutor A, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost. 1997;23(3): 303-319
22. Lane D, Lindahl U. Heparin: Chemical and Biological Properties, Clinical Applications. Boca Raton, FL: CRC Press; 1989
23. Rosenberg R, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci U S A. 1979;76(3):1218-1222
24. Wu Y, Sheffield W, Blajchman M. Defining the heparinbinding domain of antithrombin. Blood Coagul Fibrinolysis. 1994;5(1):83-95
25. Pratt C, Church F. Antithrombin: structure and function. Semin Hematol. 1991;28(1):3-9
26. Sandset P. Tissue factor pathway inhibitor (TFPI): an update. Haemostasis. 1996;26(suppl 4):154-165
27. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993; 268(36):26950-26955
28. Ostergaard P, Nordfang O, Petersen L, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrom-botic effect of heparins? Biochemical considerations. Haemostasis. 1993;23(suppl 1):107-111
29. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80(8):1998-2005
30. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362-372
31. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost. 1994;72(6):836-842
32. Ignjatovic V, Furmedge J, Newall F, et al. Age-related differences in heparin response. Thromb Res. 2006;118(6):741-745
33. Schmidt B, Mitchell L, Ofosu F, Andrew M. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemost. 1989; 62(4):1074-1077
34. Schmidt B, Ofosu F, Mitchell L, Brooker L, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res. 1989;25(4):405-408
35. Chan A, Berry L, Monagle P, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost. 2002;87(4):606-613
36. Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan MR. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res. 1988;52(6):517-527
37. Andrew M, Ofosu F, Brooker L, Buchanan M. The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thromb Res. 1989;56(4):529-539
38. McDonald M, Jacobson L, Hay WJ, Hathaway W. Heparin clearance in the newborn. Pediatr Res. 1981;15(7):1015-1018
39. Hull R, Raskob G, Hirsh J, et al. Continuous intravenous hep-arin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315(18):1109-1114
40. Hull R, Raskob G, Rosenbloom D, et al. Heparin for 5 days as compared to 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322(18):1260-1264
41. Turpie A, Robinson J, Doyle D, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320(6):352-357
42. Brill-Edwards P, Ginsberg J, Johnston M, Hirsh J. Establishing Treatment of Neonatal Thrombosis. Thromb Haemost. 1992; 67(3):381-382 a therapeutic range for heparin therapy. Ann Intern Med. 1993; 119(2):104-109
43. 43.Hull RD. Anticoagulant treatment. Int Angiol. 1995;14(1): 32-44
44. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest. 2004;126(3 suppl):188S-203S
45. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost. 2006;4(10):2280-2282
46. Chan AK, Black L, Ing C, Brandao LR, Williams S. Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res. 2008;122(1):135-136
47. Kuhle S, Eulmesekian P, Kavanagh B, et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica. 2007;92(4):554-557
48. Laffan M, Manning R. Laboratory control of anticoagulant, thrombolytic and anti-platelet therapy. In: Lewis S, Bain B, Bates I, eds. Dacie and Lewis: Practical Haematology. 9th ed. London, United Kingdom: Churchill Livingstone; 2001: 465-479
49. Olson J, Arkin C, Brandt J, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782-798
50. Kitchen S, Theaker J, Preston F. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis. 2000; 11(2):137-144
51. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111(2):397-406
52. Walenga J, Fareed J, Hoppensteadt D. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight heparin. Semin Thromb Hemost. 1985; 11(1):17-25
53. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49-56
54. Barrowcliffe T, Mulloy B, Johnson E, Thomas D. The anticoagulant activity of heparin: measurement and relationship to chemical structure. J Pharm Biomed Anal. 1989;7(2):217-226
55. Triplett D. Heparin: biochemistry, therapy, and laboratory monitoring. Ther Drug Monit. 1979;1(2):173-197
56. Nelson D. Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci. 1999;12(6): 359-364
57. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res. 2007;120(3):347-351
58. Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med. 1988;112(5):641-643
59. Soloway H, Cox S. In vitro comparison of the thrombin time and activated partial thromboplastin time in the laboratory control of heparin therapy. Am J Clin Pathol. 1973;60(5): 648-650
60. Levine M, Raskob G, Beyth R, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):287S-310S
61. Wilson J, Bynum L, Parkey R. Heparin therapy in venous thromboembolism. Am J Med. 1981;70(4):808-816
62. Norman C, Provan J. Control and complications of intermittent heparin. Surg Gynecol Obstet. 1977;145(3):338-342
63. Urokinase Pulmonary Embolism Trial: morbidity and mortality. Circulation. 1973;47(suppl 2):66-72
64. Warkentin T, Kelton J. Interaction of heparin with platelets, including heparin induced thrombocytopenia. In: Bou-nameaux H, ed. Low-Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York, NY: Marcel Dekker; 1994:75-127
65. Warkentin T, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest. 2005;127(1):416]. Chest. 2004;126(3 suppl):311S-337S
66. Warkentin T, Sheppard J, Moore J, Sigouin C, Kelton J. Quantitative interpretation of optical density measurements usingPF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312
67. Spadone D, Clark F, James E, Laster J, Hoch J, Silver D. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg. 1992;15(2):306-311; discussion 311-312
68. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost. 2001;27(3):293-299
69. Shaughnessy S, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995;86(4):1368-1373
70. Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet. 1992;340(8827): 1098